Content
Search
Navigation
Sitemap

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Cell therapy companies
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
all Gene therapy companies
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
OMass Therapeutics

09.08.22

Freeline Reports Second Quarter 2022 Financial Results and Business Highlights

Operating News
Gene therapy
Freeline Therapeutics

26.07.22

Purespring Therapeutics Expands Senior Team with Key Appointments

Operating News
Gene therapy
Purespring Therapeutics

21.07.22

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

Operating News
Gene therapy
Freeline Therapeutics

18.07.22

Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform

Operating News
Gene therapy
Purespring Therapeutics

27.06.22

SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments

Operating News
Gene therapy
SwanBio Therapeutics

24.06.22

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Operating News
Gene therapy
Freeline Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and Insights
Investors
Contact

Copyright © Syncona 2022
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

GBX 197.20

Change: -7.80 (-3.80%)

Search

Search